AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9583844 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg ascorbic acid
Number of subjects: 20
Study 9583844 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg ascorbic acid
Number of subjects: 20
Study 7633987 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 51
Study 7633987 — intervention group
Group type: COMPARATOR
Intervention: Analgesic treatment (control)
Number of subjects: 51
Study 2144216 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 102
Study 2144216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 190970 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment
Number of subjects: 374
Study 190970 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 374
Study 31596044 — intervention group
Group type: EXPERIMENTAL
Intervention: LARIAT group
Number of subjects: 153
Study 31596044 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 153
Study 29136625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated salt (250 mg F-/kg salt) used in meals for the intervention group
Number of subjects: 441
Study 29136625 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoridated salt used in meals)
Number of subjects: 441
Study 29136625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated salt intervention
Number of subjects: 441
Study 25834206 — intervention group
Group type: EXPERIMENTAL
Intervention: Integral-based hatha yoga (2 classes of 60 minutes each and 1 home practice per week for 8 weeks)
Number of subjects: 75
Study 25834206 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 75
Study 23233657 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (50 mg daily for 2 years)
Number of subjects: 96
Study 23233657 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib maintenance
Number of subjects: 96
Study 22159782 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (retinol, β‐carotene, α‐tocopherol, ascorbic acid, selenium)
Number of subjects: 274
Study 19902288 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative chemotherapy
Number of subjects: 0
Study 19902288 — intervention group
Group type: COMPARATOR
Intervention: Surgical control arm
Number of subjects: 0
Study 17872899 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy in ER-negative/PrPc-positive disease
Number of subjects: 756
Study 17872899 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy in ER-negative/PrPc-negative tumors
Number of subjects: 756
Study 15480326 — intervention group
Group type: EXPERIMENTAL
Intervention: Coseasonal sublingual immunotherapy (SLIT) for 3 years
Number of subjects: 113
Study 15480326 — intervention group
Group type: COMPARATOR
Intervention: Standard symptomatic therapy (control)
Number of subjects: 113
Study 11568050 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarctation patients
Number of subjects: 64
Study 11568050 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 64
Study 9764616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (400 mg orally)
Number of subjects: 83
Study 9764616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 7919903 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium infusion (GIK)
Number of subjects: 40
Study 7919903 — intervention group
Group type: COMPARATOR
Intervention: Control group (R)
Number of subjects: 40
Study 2837991 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day b.i.d. combined with FT‐207 600 mg/day t.i.d.
Number of subjects: 0
Study 31988343 — intervention group
Group type: EXPERIMENTAL
Intervention: Affinity-matured variants of nimotuzumab (K4 and K5)
Number of subjects: 0
Study 31988343 — intervention group
Group type: COMPARATOR
Intervention: Nimotuzumab (original)
Number of subjects: 0
Study 31174946 — intervention group
Group type: EXPERIMENTAL
Intervention: AffinosÂ®
Number of subjects: 34
Study 31174946 — intervention group
Group type: COMPARATOR
Intervention: OSferionÂ® (control group)
Number of subjects: 34
Study 28961815 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine antibiotic prescription monitoring and feedback based on health insurance claims data
Number of subjects: 250
Study 26616809 — intervention group
Group type: EXPERIMENTAL
Intervention: IMA high ligation group (63 cases, cutting distance of 1.0 to 1.5 cm to the root of IMA)
Number of subjects: 128
Study 26616809 — intervention group
Group type: COMPARATOR
Intervention: IMA low ligation group (65 cases, cutting distance of 0.5 to 1.0 cm to the root of left colic artery)
Number of subjects: 128
Study 26616809 — intervention group
Group type: EXPERIMENTAL
Intervention: IMA high ligation group
Number of subjects: 128
Study 26616809 — intervention group
Group type: COMPARATOR
Intervention: IMA low ligation group
Number of subjects: 128
Study 26616809 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 128
Study 22903141 — intervention group
Group type: EXPERIMENTAL
Intervention: Steep Ramp Test (SRT); performed twice within 2 weeks; main outcome: Peak Work Rate (WRpeak)
Number of subjects: 75
Study 22903141 — intervention group
Group type: EXPERIMENTAL
Intervention: Steep Ramp Test (SRT)
Number of subjects: 75
Study 22903141 — intervention group
Group type: COMPARATOR
Intervention: Regular Cardiopulmonary Exercise Test (CPET) with respiratory gas analysis; performed within 2 weeks; main outcome: Peak Oxygen Uptake (VO2peak)
Number of subjects: 75
Study 21483491 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ART (≤4 ARVs)
Number of subjects: 368
Study 21483491 — intervention group
Group type: COMPARATOR
Intervention: Intensive ART (≥5 ARVs)
Number of subjects: 368
Study 21483491 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate retreatment initiation
Number of subjects: 368
Study 21483491 — intervention group
Group type: COMPARATOR
Intervention: Interruption before re‐treatment
Number of subjects: 368
Study 21483491 — intervention group
Group type: EXPERIMENTAL
Intervention: Re‐treatment options
Number of subjects: 368
Study 19483372 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (3 times per week for 6 months)
Number of subjects: 60
Study 19483372 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 16765793 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporine 0.05% ophthalmic emulsion
Number of subjects: 21
Study 16765793 — intervention group
Group type: COMPARATOR
Intervention: unpreserved artificial tears
Number of subjects: 21
Study 14756932 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependents (18)
Number of subjects: 100
Study 11087764 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (0.4 g/kg/d for 5 consecutive days)
Number of subjects: 16
Study 11087764 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 16
Study 11087764 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose or saline)
Number of subjects: 16
Study 11087764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8936445 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboccipital manipulation (slow, steady, circular kneading)
Number of subjects: 25
Study 8936445 — intervention group
Group type: COMPARATOR
Intervention: Touching the suboccipital region (control)
Number of subjects: 25
Study 8936445 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboccipital manipulation
Number of subjects: 25
Study 1609951 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg/kg
Number of subjects: 200
Study 1609951 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.5 mg/kg
Number of subjects: 200
Study 1609951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 1609951 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.25 mg/kg
Number of subjects: 200
Study 4082242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg every 6 h (Phase B)
Number of subjects: 18
Study 4082242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg every 6 h (Phase C)
Number of subjects: 18
Study 4082242 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (5 mg/kg) (Phase A)
Number of subjects: 18
Study 30261748 — intervention group
Group type: EXPERIMENTAL
Intervention: VacuMed® treatment thrice weekly for 6 weeks
Number of subjects: 48
Study 30261748 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle changes
Number of subjects: 48
Study 29889382 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA monotherapy
Number of subjects: 42
Study 29889382 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA + Hymecromone
Number of subjects: 42
Study 24878521 — intervention group
Group type: EXPERIMENTAL
Intervention: E-health4Uth
Number of subjects: 1256
Study 24878521 — intervention group
Group type: EXPERIMENTAL
Intervention: E-health4Uth and consultation
Number of subjects: 1256
Study 24878521 — intervention group
Group type: EXPERIMENTAL
Intervention: E-health4Uth and consultation (subgroup at risk of mental health problems)
Number of subjects: 1256
Study 24878521 — intervention group
Group type: COMPARATOR
Intervention: Control group (care as usual)
Number of subjects: 1256
Study 22494671 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 203
Study 22494671 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitors (CNI)
Number of subjects: 203
Study 20598621 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline demographic parameters (education and age)
Number of subjects: 0
Study 20598621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive measures (RBANS, FAB, Letter-Number Sequencing)
Number of subjects: 0
Study 20598621 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of symptomatic therapy
Number of subjects: 0
Study 18036365 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day rosuvastatin
Number of subjects: 17802
Study 18036365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17802
Study 16037102 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-cholesterol levels
Number of subjects: 80
Study 16037102 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative remodelling (RI<1)
Number of subjects: 80
Study 16037102 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol levels
Number of subjects: 80
Study 16037102 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein-B levels
Number of subjects: 80
Study 12447338 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia with normocapnia
Number of subjects: 14
Study 12447338 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen treatment
Number of subjects: 14
Study 10696278 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapting subjects to an unambiguous version of the figure before presentation of the traditional reversible figure.
Number of subjects: 0
Study 8623801 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized dehydroepiandrosterone 300 mg
Number of subjects: 12
Study 8623801 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral crystalline dehydroepiandrosterone 300 mg
Number of subjects: 12
Study 8623801 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal micronized dehydroepiandrosterone 150 mg
Number of subjects: 12
Study 8623801 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized dehydroepiandrosterone 150 mg
Number of subjects: 12
Study 8623801 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study 1952858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil at 250 mg
Number of subjects: 24
Study 1952858 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor at 250 mg
Number of subjects: 24
Study 1952858 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor at 375 mg
Number of subjects: 24
Study 1952858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil at 250 mg and cefaclor at 375 mg twice daily or cefaclor at 250 mg three times daily
Number of subjects: 24
Study 7039204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1.2 grams daily for 35 days)
Number of subjects: 10
Study 7039204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31433518 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate (ZOL) 5 mg infusion
Number of subjects: 57
Study 31433518 — intervention group
Group type: COMPARATOR
Intervention: Denosumab (Dmab) 60 mg injections (2 additional injections)
Number of subjects: 57
Study 29970736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (Group A) 1 mg/kg for two weeks
Number of subjects: 31
Study 29970736 — intervention group
Group type: EXPERIMENTAL
Intervention: IV methylprednisolone (Group B) 30 mg/kg for three days followed by oral prednisolone 1 mg/kg for two weeks
Number of subjects: 31
Study 26829376 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Assessment (TA)
Number of subjects: 10
Study 24866862 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, moderate-intensity physical activity program (n=818)
Number of subjects: 1635
Study 24866862 — intervention group
Group type: COMPARATOR
Intervention: Health education program (n=817)
Number of subjects: 1635
Study 22774791 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Methods/Homework
Number of subjects: 176
Study 22774791 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment (Cognitive Therapy + Antidepressant medication)
Number of subjects: 176
Study 20716770 — intervention group
Group type: EXPERIMENTAL
Intervention: Zosuquidar (550 mg)
Number of subjects: 449
Study 20716770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 17926625 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Number of subjects: 11
Study 17926625 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (control)
Number of subjects: 11
Study 16374982 — intervention group
Group type: EXPERIMENTAL
Intervention: General sites
Number of subjects: 253
Study 16374982 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific non-commercial sites
Number of subjects: 253
Study 12422079 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (ampicillin/sulbactam, 25 mg/kg/daily)
Number of subjects: 62
Study 12422079 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment combined with intranasal budesonide (200 mg/daily)
Number of subjects: 62
Study 12422079 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 62
Study 11938741 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg administered intravenously)
Number of subjects: 62
Study 11938741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diazepam administered)
Number of subjects: 62
Study 7583507 — intervention group
Group type: EXPERIMENTAL
Intervention: Female veterans with affective disorders and schizoaffective disorder
Number of subjects: 51
Study 7583507 — intervention group
Group type: COMPARATOR
Intervention: Male veterans with anxiety disorders, schizophrenia, and substance use disorders
Number of subjects: 51
Study 7583507 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma history in female veterans
Number of subjects: 51
Study 7583507 — intervention group
Group type: COMPARATOR
Intervention: Posttraumatic stress disorder diagnosis
Number of subjects: 51
Study 7583507 — intervention group
Group type: COMPARATOR
Intervention: Marital status
Number of subjects: 51
Study 7583507 — intervention group
Group type: EXPERIMENTAL
Intervention: Caretaking responsibilities
Number of subjects: 51
Study 2046138 — intervention group
Group type: EXPERIMENTAL
Intervention: CV-4151 (selective inhibitor of thromboxane A2 synthetase), administered greater than or equal to 2 days before angioplasty and continued until follow-up (3-6 months after angioplasty)
Number of subjects: 85
Study 2046138 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 85
Study 6459027 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin plus amikacin
Number of subjects: 38
Study 6459027 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin plus amikacin
Number of subjects: 38
Study 31085099 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid presentations
Number of subjects: 166
Study 31085099 — intervention group
Group type: COMPARATOR
Intervention: Traditional lectures
Number of subjects: 166
Study 28650194 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered parent-child interaction therapy (I-PCIT)
Number of subjects: 40
Study 28650194 — intervention group
Group type: COMPARATOR
Intervention: clinic-based parent-child interaction therapy (PCIT)
Number of subjects: 40
Study 26076571 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic glucose metabolism disorders (A)
Number of subjects: 130
Study 26076571 — intervention group
Group type: COMPARATOR
Intervention: Control group (B)
Number of subjects: 130
Study 24289181 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of atrial fibrillation (AF)
Number of subjects: 1500
Study 24289181 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination of primary and secondary care
Number of subjects: 1500
Study 24289181 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient engagement and support
Number of subjects: 1500
Study 21550018 — intervention group
Group type: EXPERIMENTAL
Intervention: Adopting a distanced stance (third-person perspective)
Number of subjects: 0
Study 19549020 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,800 mg/d EPA-DHA (n=96)
Number of subjects: 302
Study 19549020 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/d EPA-DHA (n=100)
Number of subjects: 302
Study 19549020 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (n=106)
Number of subjects: 302
Study 17405474 — intervention group
Group type: EXPERIMENTAL
Intervention: Renewed generation VICRYL rapide (n = 60)
Number of subjects: 120
Study 17405474 — intervention group
Group type: COMPARATOR
Intervention: Original generation VICRYL rapide (n = 60)
Number of subjects: 120
Study 10799351 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 200 microgram s.c. 3 times daily, starting the night before endoscopic procedures
Number of subjects: 94
Study 10799351 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3 times daily, starting the night before endoscopic procedures
Number of subjects: 94
Study 10799351 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 94
Study 10799351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 8851809 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanics
Number of subjects: 1919
Study 8851809 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic abstainers
Number of subjects: 1919
Study 8851809 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic Whites
Number of subjects: 1919
Study 1381640 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin, 400 mg i.v., given as a single dose
Number of subjects: 0
Study 1381640 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 6387059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Adriamycin, Cisplatin (CAP) followed by Cyclophosphamide, 5-Fluorouracil, Prednisone (CFP)
Number of subjects: 86
Study 6387059 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, 5-Fluorouracil, Prednisone (CFP)
Number of subjects: 86
Study 30523756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and Etoposide with Veliparib (CE+V)
Number of subjects: 128
Study 30523756 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and Etoposide with Placebo (CE+P)
Number of subjects: 128
Study 30388039 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL-deficient condition
Number of subjects: 8
Study 30388039 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL-/ALL-deficient condition
Number of subjects: 8
Study 30388039 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-N·m load after ACL and ALL sectioning
Number of subjects: 8
Study 30388039 — intervention group
Group type: COMPARATOR
Intervention: Supra- and inframeniscal ALL sectioning
Number of subjects: 8
Study 26063054 — intervention group
Group type: EXPERIMENTAL
Intervention: Good sleep at baseline
Number of subjects: 409
Study 26063054 — intervention group
Group type: COMPARATOR
Intervention: Impaired sleep at baseline
Number of subjects: 409
Study 24901761 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic postural stability training program using the Biodex Stability System
Number of subjects: 30
Study 24901761 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy program
Number of subjects: 30
Study 23157899 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU
Number of subjects: 72
Study 23157899 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 72
Study 23157899 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE + HIFU
Number of subjects: 72
Study 20141299 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 0
Study 20141299 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted Controls
Number of subjects: 0
Study 17622289 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CON)
Number of subjects: 44
Study 17622289 — intervention group
Group type: COMPARATOR
Intervention: Control diet with exercise (CONEx)
Number of subjects: 44
Study 17622289 — intervention group
Group type: COMPARATOR
Intervention: High-protein diet (HP)
Number of subjects: 44
Study 17622289 — intervention group
Group type: COMPARATOR
Intervention: High-protein diet with exercise (HPEx)
Number of subjects: 44
Study 16122283 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed moxifloxacin 400 mg tablet as a suspension through a nasogastric tube with water (regimen B)
Number of subjects: 12
Study 16122283 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed moxifloxacin 400 mg tablet as a suspension through a nasogastric tube with enteral feeding (regimen C)
Number of subjects: 12
Study 16122283 — intervention group
Group type: COMPARATOR
Intervention: Intact moxifloxacin 400 mg tablet (regimen A, reference treatment)
Number of subjects: 12
Study 11849412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 51